Platine’s laboratories located in Lyon, France, will help clients in the biopharmaceutical, food, cosmetic and diagnostic industries to assess the immunogenicity, activity and efficacy of products during R&D, preclinical and human clinical studies.
The company offers immunologic expertise and services using a broad range of in vitro platforms such as flow cytometry, ELISpot, ELISA, multiplex, Singulex, and MSD capabilities.
It also provides its Immuno’line T-cell activation service to evaluate the specific immune response to a particular therapeutic drug, vaccine, cosmetic, or food product of interest.
ABL president and CEO Thomas VanCott said: "We are extremely excited to have the Platine organization join ABL.
"Over the years, their staff of dedicated and highly talented scientists has proven their ability to deliver the highest quality of service, meeting clients’ immunological testing needs throughout the product development process.
"This acquisition also represents a significant step in the strategic growth of ABL, providing a European-based facility for clinical and other sample processing and immunomonitoring analyses.
"With laboratories based in France and the U.S., ABL is better positioned to support our clients’ increasingly global clinical development strategies."